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Background: Atrial fibrillation (AF) is a common arrhythmia in the ICU. The aim of this review is to summarize
relevant information on new-onset AF in non-cardiac critical illness with respect to epidemiology, prevention, and
treatment.
Methods: We conducted a PubMed search in June 2014 and included studies describing the epidemiology,
prevention, and treatment of new-onset AF and atrial flutter during ICU stay in non-cardiac adult patients. Selected
studies were divided into the three categories according to the extracted information. The methodological quality
of selected studies was described according to the Grading of Recommendations Assessment, Development and
Evaluation system.
Results: We identified 1,132 citations, and after full-text-level selection, we included 10 studies on etiology/outcome
and five studies on treatment. There was no study related to prevention. Overall quality of evidence was mostly low
or very low due to their observational study designs, small sample sizes, flawed diagnosis of new-onset AF, and the
absence of mortality evaluation. The incidence of new-onset AF varied from 4.5% to 15.0%, excluding exceptional
cases (e.g., septic shock). Severity scores of patients with new-onset AF were higher than those without new-onset
AF in eight studies, in four of which the difference was statistically significant. Five studies reported risk factors for
new-onset AF, all of which used multivariate analyses to extract risk factors. Multiple risk factors are reported, e.g.,
advanced age, the white race, severity scores, organ failures, and sepsis. Hospital mortality in new-onset AF patients
was higher than that of patients without AF in all studies, four of which found statistical significance. Among the
five studies on treatment, only one study was randomized controlled, and various interventions were studied.
Conclusions: New-onset AF occurred in 5%–15% of the non-cardiac critically ill patients. Patients with new-onset
AF had poor outcomes compared with those without AF. Despite the high incidence of new-onset AF in the
general ICU population, currently available information for AF, especially for management (prevention, treatment,
and anticoagulation), is quite limited. Further research is needed to improve our understanding of new-onset AF in
critically ill patients.
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Atrial fibrillation (AF) is a common arrhythmia in
critically ill patients [1-4]. To date, multiple studies on
incidence, prophylaxis, and treatment of new-onset AF
in specific cohorts have been published, such as cardiac
surgery [5-15], non-cardiac surgery [16-23], and med-
ical diseases [24-27]. Especially in cardiac surgery and
cardiac diseases, incidence and treatment of AF have
been extensively investigated, which have led to publi-
cation of many reviews and established recommenda-
tions in guidelines [28-35]. Compared with the amount
of knowledge for cardiac diseases, however, information
on AF occurring in general critically ill populations is
limited [36,37].
Another issue related to AF in critically ill patients is
their ambiguous inclusion criteria of the study popula-
tion, in which supraventricular arrhythmia (SVA) or
atrial tachycardia was often grouped with AF and atrial
flutter [1,16,19,24]. AF and atrial flutter are different
from SVA or atrial tachycardia in pathophysiology that
lies behind them and treatment goals [38-40]. The goal
of treatment for AF and atrial flutter might be rhythm
conversion to improve cardiac output and preventing
thromboembolic events [32-34,41-47]. However, a lack
of information concentrating on AF and atrial flutter
makes it difficult to decide whether clinicians should do
any interventions for the arrhythmia.
The aim of this review is to summarize relevant infor-
mation concentrating on new-onset AF in non-cardiac
critically ill patients with respect to epidemiology, preven-
tion, and treatment.
Methods
Data sources and searches
We conducted a PubMed search in June 2014 using the
following MeSH and keyword terms: “atrial fibrillation”
or “atrial flutter” or “(atrial or supraventricular) and
(tachycardia or tachyarrhythmia or arrhythmia)” and “in-
tensive care” or “critical care” or “critically ill” or “critical
illness.” Only articles published in English were consid-
ered for this systematic review.
Study selection
The primary author (TY) and the secondary author (TF)
independently screened titles and abstracts of articles
identified by the search and checked in full-text level for
concise selection. We included studies describing the
epidemiology, prevention, and treatment of new-onset
AF and atrial flutter during ICU stay in non-cardiac
adult patients. Exclusion criteria were studies without
description of settings as ICU, studies that focused ex-
clusively on a perioperative period of a specific proced-
ure, studies mainly on patients with heart diseases and
cardiac surgery, and studies that did not exclude patientswith past history of AF. We also excluded reviews and
commentaries that did not contain original information
and reports that were published only in abstract form
and that provided no clear definition of patients or ar-
rhythmias studied. Reports on patients with severe sepsis
and septic shock but that were not specifically mentioned
to be conducted in the ICU were included because those
patients were highly expected to have been in the ICU.
While atrial flutter was included because of its risk of
thromboembolic events similar to AF, SVA, which was not
specified further, was excluded in this review as it was out
of our scope as mentioned above. Disagreement was
adjudicated through consensus of the two reviewers.
As this study of a systematic review did not contain
human research, approval of an institutional review board
was waived.
Data extraction and quality assessment
The primary author (TY) extracted information for the
systematic review and undertook quality assessment.
Selected studies were divided into three categories ac-
cording to the extracted information: etiology/outcome,
prevention, and treatment. The methodological quality
of selected studies was described according to the
Grading of Recommendations Assessment, Development
and Evaluation (GRADE) system [48]. Extracted data to
evaluate the risk of bias, indirectness, and imprecision
were as follows: details of diagnosis of AF, allocation
concealment, blinding, detailed description of conversion
from AF to sinus rhythm, applicability of each study popu-
lation, reported outcome, and sample sizes. We scored all
items and classified into four categories from very low to
high as overall quality.
Results
Figure 1 shows the flow chart of studies selected in the
systematic review. We identified 1,132 citations and 66
studies were evaluated in full-text review. Thirty-two of
the 66 studies related to etiology/outcome, nine studies
related to prevention, and 26 studies related to treat-
ment. After full-text-level selection, we included in this
review ten studies on etiology/outcome [26,49-57] and
five studies on treatment [51,53,55,58,59]. On the other
hand, there was no study related to prevention that
could be included in this review. Although there were
two studies on prevention performed in the ICU, they
focused on patients after lung resection surgery and thus
were excluded [60,61]. Three studies were related to
both etiology/outcome and treatment [51,53,55]. In the
study by Balser et al., they screened SVA and included
only those who did not convert to sinus rhythm after an
adenosine challenge to rule out reentrant atrioventricu-
lar nodal rhythm and ventricular tachyarrhythmia, so
that this study was included in this review [58].
Records identified through database searching N=1,132
Excluded after title and abstract review : N=1,066







Excluded on full text
N=5 not conducted in ICU 
N=10 not focusing on new onset AFib or AFl
N=4 including cardiac diseases
N=1 small case series
N=1 review article
N=1 not appropriate outcome
Excluded on full text
N=4 not conducted in ICU 
N=3 not focusing on new onset AFib or AFl
N=2 focused on a specific procedure
Excluded on full text
N=1 not conducted in ICU 
N=8 not focusing on new onset AFib or AFl
N=11 including cardiac diseases








Figure 1 Flow chart of studies selected in the systematic review. AFib: atrial fibrillation, AFl: atrial flutter.
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studies. Of the ten studies for etiology/outcome, three
studies were retrospective studies and the others were pro-
spective. Of the five studies for treatment, there was only
one randomized controlled trial (RCT). The number of
patients included in each study varied from 29 to 49,082.
Although one study was not performed in the ICU, it met
our criteria as it was of septic shock patients [54].
Table 2 shows the methodological quality of included
studies. Overall quality of evidence was low or very lowTable 1 Overall characteristics of included studies
Author, year [ref] Study design No. of p
Bender JS, 1996 [49] Prospective observational 206
Seguin P, 2004 [50] Prospective observational 453
Seguin P, 2006 [51] Prospective observational 293
Arora S, 2007 [52] Prospective observational 61
Christian SA, 2008 [26] Retrospective observational 272
Meierhenrich R, 2010 [53] Prospective observational 629 (50
Walkey AJ, 2011 [54] Retrospective population-based cohort 49,082
Kanji S, 2012 [55] Retrospective observational 3,081
Tongyaoo S, 2013 [56] Prospective observational 247
Makrygiannis SS, 2014 [57] Prospective observational 133
Balser JR, 1998 [60] Randomized controlled 64a
Sleeswijk ME, 2008 [61] Prospective observational 29
aNumber of patients with supraventricular tachyarrhythmia (not focusing on AFib adue to their observational study designs, small sample
sizes, flawed diagnosis of new-onset AF, and the absence
of mortality evaluation.
Table 3 shows incidences of AF and severity scores of
the study population. In four studies performed in the
surgical ICU, the incidence of new-onset AF was similar,
ranging from 5.3% to 7.8% [49-51,54]. The incidence
varied from 4.5% to 29.5% in four studies performed in
the mixed ICU [26,52,55,57]. In a single study performed
in the medical ICU, the incidence of AF was 13.8% [56].atients Setting (patients) Outcome
Surgical ICU Etiology
Surgical ICU Etiology/outcome
Surgical ICU (trauma) Etiology/outcome treatment
Mixed ICU Etiology/outcome
Mixed ICU (sepsis) Etiology/outcome










Table 2 Methodological quality of included studies
Author, year [ref] Main outcome Study design Risk of bias Indirectness Imprecisiona Overall quality
Bender JS, 1996 [49] Etiology/outcome Prospective (0.5), observational (2) AF diagnosis unclear (−1) Mortality not evaluated (−0.5) Very low (1)
Seguin P, 2004 [50] Etiology/outcome Prospective (0.5), observational (2) Low (2.5)
Seguin P, 2006 [51] Etiology/outcome Prospective (0.5), observational (2) Only trauma patients (−0.5) Low (2)
Seguin P, 2006 [51] Treatment Prospective (0.5), observational (2) Absence of definition for
conversion time (−1)
N = 16 (−1) Very low (0.5)
Arora S, 2007 [52] Etiology/outcome Prospective (0.5), observational (2) N = 61 (−1) Very low (1.5)
Christian SA, 2008 [26] Etiology/outcome Observational (2) Retrospective diagnosis of AF
(−1)
Only septic patients (−0.5) Very low (0.5)
Meierhenrich R, 2010 [53] Etiology/outcome Prospective (0.5), observational (2) Low (2.5)
Meierhenrich R, 2010 [53] Treatment Prospective (0.5), observational (2) Unknown efficacy of each
treatment (−1)
N = 49 (−1) Very low (0.5)
Walkey AJ, 2011 [54] Etiology/outcome Observational (2) Retrospective diagnosis of AF
(−1)
Only septic patients (−0.5) N = 49,082 (+2) Low (2.5)
Kanji S, 2012 [55] Etiology/outcome Observational (2) Retrospective diagnosis of AF
(−1)
N = 2,895 (+1) Low (3)
Kanji S, 2012 [55] Treatment Observational (2) Retrospective diagnosis of AF
(−1)
Unknown efficacy of each
treatment (−1)
Very low (0)
Tongyaoo S, 2013 [56] Etiology/outcome Prospective (0.5), observational (2) Low (2.5)
Makrygiannis SS, 2014 [57] Etiology/outcome Prospective (0.5), observational (2) Mortality not evaluated (−0.5) Low (2)
Balser JR, 1998 [60] Treatment Randomized (4) Open label (−0.5), Allocation
concealment unclear (−0.5)
Mortality not evaluated (−0.5) N = 64 (−1) Very low (1.5)
Sleeswijk ME, 2008 [61] Treatment Prospective (0.5), observational (2) Mortality not evaluated (−0.5) N = 29 (−1) Very low (1)











Table 3 Incidences of new-onset atrial fibrillation and severity scores of the study population
Author, year [ref] Setting patients Incidence of AF (no.) Severity score Mean scorea
Bender JS, 1996 [49] Surgical ICU 6.8% (14/206) NA NA
Seguin P, 2004 [50] Surgical ICU 5.3% (24/453) SAPS II 45 vs. 31 (p = 0.0001)
Seguin P, 2006 [51] Surgical ICU (trauma) 5.5% (16/293) SAPS II 47 vs. 31 (p < 0.001)
Arora S, 2007 [52] Mixed ICU 29.5% (18/61) APACHE II 25.4 vs. 20.0 (p = 0.005)
SAPS II 47.8 vs. 37.1 (p = 0.001)
Christian SA, 2008 [26] Mixed ICU (sepsis) 5.9% (16/272) APACHE II predicted survival 49% vs. 55% (p = 0.36)
Meierhenrich R, 2010 [53] Surgical ICU All patients 7.8% (49/629) SAPS II NA
Septic shock 46.0% (23/50) 31 vs. 30b (p = 0.12)
Walkey AJ, 2011 [54] Acute care hospitals (severe sepsis) 5.9% (2,896/49,082) Number of organ failures 3.11 vs. 3.08b (p = 0.42)
Kanji S, 2012 [55] Three mixed ICUs 4.5% (139/3,081) APACHE II 22.6c
Tongyaoo S, 2013 [56] Medical ICU 13.8% (34/247) APACHE II 24.4 vs. 17.0d (p < 0.001)
Makrygiannis SS, 2014 [57] Mixed ICU 15.0% (20/133) APACHE II 17.9 vs. 15.7 (p = 0.16)
AF atrial fibrillation, APACHE II Acute Physiology and Chronic Health Evaluation II, SAPS II Simplified Acute Physiology Score II, NA not available.
aAtrial fibrillation vs. no atrial fibrillation.
bMedian.
cNo information for APACHE II in no new-onset AF patients provided.
dAll types of supraventricular tachyarrhythmia included.
Yoshida et al. Journal of Intensive Care  (2015) 3:19 Page 5 of 11When focused on sepsis and severe sepsis, new-onset
AF occurred in 5.9% of septic patients [26,54], which
was similar to that in surgical ICU populations. How-
ever, the incidence jumped up to 46.0% in patients with
septic shock [53]. Most studies reported a severity of
illness with Simplified Acute Physiology Score (SAPS) II
[62] or Acute Physiology and Chronic Health Evaluation
(APACHE) II score [63]. Severity scores of patients with
new-onset AF were reported to be higher than those
without new-onset AF in eight studies, in four of which
the difference was statistically significant [50-52,56].
Table 4 shows a list of risk factors for new-onset AF.
Five studies reported risk factors for new-onset AF, all of
which used multivariate analyses to extract risk factors
[50-52,55,58]. All studies reported advanced age in com-
mon, two studies reported right heart catheter [50,55],
and two studies reported sepsis [52,58] as independent
risk factors. Medication with β-blocking agents was
shown not to have any relationship with new-onset AF
in three studies [50-52]. In turn, one study reported that
medication with calcium channel blockers had a positive
relationship with the incidence of new-onset AF [50].
Severity of illness was evaluated in four studies, three of
which found severity of illness (SAPS II ≥ 30, shock,
three or more regions traumatized, SIRS, APACHE II
score ≥20) to have high odds ratios for new-onset AF
with statistical significance.
Table 5 and Figure 2 show outcomes of new-onset AF.
Among eight studies reporting outcomes of AF patients,
new-onset AF was associated with increased ICU length
of stay in four studies [26,50,51,53] and increased hos-
pital length of stay in one study [50]. Three studies re-
ported the incidence of stroke that ranged from 0% to5.9% [54-56]. A large cohort study of severe sepsis
showed a significantly higher incidence of stroke in the
new-onset AF group compared with the non-AF group
(2.6% vs. 0.7%, p < 0.0001) [54]. Only one study referred
to systemic therapeutic anticoagulation, in which 16% of
the patients with new-onset AF were treated [55]. None
of the study patients with new-onset AF had a stroke
during the course of AF. Hospital mortality rates in
new-onset AF groups were higher than those of no-AF
groups in seven studies, in which four studies found
statistical significance (Figure 2) [26,50,52,54]. However,
none of the studies evaluated the impact of new-onset
AF on mortality with multivariate analysis including
severity scores.
Table 6 shows the efficacy of treatment for new-onset
AF. There were five studies on treatment for new-onset
AF [51,53,55,58,59]. Balser et al., the only RCT among
the five studies, evaluated a conversion rate from AF to
sinus rhythm within 2 h after starting administration of
either esmolol or diltiazem [58]. There was no statistical
difference in the conversion rate between the two study
drugs (59.1% vs. 27.3%, p = 0.067). Kanji et al. reported a
conversion rate within 24 h after various interventions.
They did not describe details of combination of rhythm
control therapies (direct current cardioversion, amioda-
rone, sotalol) and rate control therapies (β-blockers,
calcium channel blockers, or digoxin, alone or in
combination), so that the conversion rate could not be
directly comparable to each intervention [55]. Sleeswijk
et al. evaluated an efficacy of a protocol of magnesium
sulfate (MgSO4)-amiodarone step-up scheme, which was
MgSO4 administration followed by additional adminis-
tration of amiodarone if no conversion to sinus rhythm
Table 4 Risk factors for new-onset atrial fibrillation
Category Risk factor OR (95%CI) Reference
Demographics Age > 65 years 7.0 (2.0–24.6) [58]
Age≥ 40 years 6.3 (1.4–28.7) [51]
Age≥ 75 years 4.79 (1.16–19.8) [52]
Age, per 10 years 1.52 (1.47–1.56) [54]
Advanced age 1.04 (1.01–1.07) [50]




Black (white as reference) 0.67 (0.58–0.78) [54]
Past history Calcium channel blockers 3.87 (1.18–12.7) [50]




Obesity 1.20 (1.03–1.40) [54]
Hypertension 0.88 (0.81–0.95) [54]
Diabetes mellitus 0.82 (0.75–0.90) [54]
Severity SAPS II≥ 30 11.6 (1.3–103.0) [51]
Shock 6.77 (2.17–21.1) [50]
SIRS 4.4 (1.2–16.1) [51]
APACHE II score≥ 20 3.90 (1.00–16.7) [52]
Organ failure Respiratory failure 2.81 (2.48–3.19) [54]
Congestive heart failure 1.61 (1.41–1.83) [54]
Hematologic failure 1.50 (1.34–1.68) [54]
Renal failure 1.40 (1.26–1.56) [54]
Per organ failure 1.12 (1.05–1.19) [54]
Acidosis 0.87 (0.77–0.97) [54]
Trauma Blunt thoracic trauma 16.8 (4.00–71.2) [50]
Three or more regions
traumatized
6.2 (1.8–21.4) [51]
Infection Sepsis 6.5 (2.0–21.1) [57]
Sepsis at admission 4.87 (1.24–18.8) [52]
Abdominal infection 1.77 (1.59–1.97) [54]
Fungal infection 1.59 (1.27–2.00) [54]
Respiratory tract infection 1.27 (1.14–1.40) [54]
Skin or soft tissue
infection
1.33 (1.14–1.55) [54]
Gram-positive bacteria 1.29 (1.18–1.55) [54]
Primary bacteremia 1.17 (1.02–1.36) [54]
Urinary tract infection 0.89 (0.81–0.99) [54]
Intervention Catecholamine use 5.7 (1.7–19.1) [51]
Pulmonary artery catheter 5.46 (1.84–16.2) [50]
Right heart catheterization 2.25 (1.87–2.70) [54]
OR odds ratio, APACHE II Acute Physiology and Chronic Health Evaluation II, CI
confidence interval, SAPS II Simplified Acute Physiology Score II, SIRS systemic
inflammatory response syndrome.
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min was attained. Although this study was not a compara-
tive study, the reported conversion rate was high (93.1%)
[59]. Meierhenrich et al. reported 85.7% of a conversion
rate with various interventions, including direct current
cardioversion, amiodarone, digitalis glycosides, and β-
blockers, alone or in combination [53]. ICU mortality
was significantly higher in patients who failed to be
cardioverted than those who were converted (71.4% vs.
21.4%, p = 0.015).
Discussion
In this systematic review, we found that the incidence of
new-onset AF in non-cardiac critically ill patients widely
ranged. Meierhenrich et al. reported a high rate of AF
among septic shock patients (46.0%) [53]. Arora et al. re-
ported an incidence of 29.5% in their mixed ICU, where
more than 95% of patients were mechanically ventilated
and nearly 30% received renal replacement therapy [52].
Excluding these two studies with exceptionally severe
cases, the incidence of new-onset AF for non-cardiac crit-
ically ill patients in the general ICU was from 4.5% to
15.0%. Postoperative AF had been reported to occur in
15% to 50% of patients with cardiac surgery [32,33] and
10% to 42% with thoracic surgery [18-24], suggesting that
these two specific cohorts might have a higher incidence of
AF compared with the general ICU population. Since the
risk factor with the highest odds ratio for new-onset AF
was blunt thoracic trauma (Table 4, odds ratio = 16.8), a
directly invasive procedure or trauma on the thorax might
significantly contribute to the occurrence of new-onset AF
in critically ill patients. Nonetheless, the incidence range in
our review (5% to 15.0%) is higher than previously thought
(4% to 9%) [3], possibly due to the aging population and
development of more complex surgical procedures.
Severity of illness (APACHE II, SAPS II, SIRS, shock),
organ failures, and sepsis were all reported as risk factors of
AF in multiple studies. A subgroup of septic shock patients
also had a markedly high incidence of new-onset AF (46%)
[53]. These findings suggest that systematic inflammation
might have a role in triggering AF in critically ill patients.
Studies in cardiac surgery and the general population also
reported that systemic inflammation could trigger AF, and
there have been clinical trials using anti-inflammatory
agents, such as colchicine and corticosteroid, to prevent or
treat AF [10,12-15,64]. The effect of anti-inflammatory
agents for AF in critically ill patients is unknown and fur-
ther studies are needed. In the well-known CORTICUS
study (hydrocortisone therapy for patients with septic
shock), the incidence of AF or any types of arrhythmias
was unfortunately not reported [65].
Although studies in cardiac surgery patients showed that
β-blockers had a prophylactic effect for postoperative AF
[29-35], none of the studies in this review showed a
Table 5 Outcomes of patients with new-onset atrial fibrillation
Author, year [ref] ICU LOS (days, mean) Hospital LOS (days, mean) Stroke (%)
Seguin P, 2004 [50] 16 vs. 7 (p = 0.0001) 34 vs. 22 (p = 0.009) NA
Seguin P, 2006 [51] 22 vs. 10 (p < 0.001) 32 vs. 25 (p = 0.259) NA
Arora S, 2007 [52] 10 vs. 4a (NS) 47 vs. 22a (NS) NA
Christian SA, 2008 [26] 17.7 vs. 8.3 (p = 0.003) 32.1 vs. 28.5 (p = 0.68) NA
Meierhenrich R, 2010 [53] 30 vs. 17ab (p = 0.017) NA NA
Walkey AJ, 2011 [54] NA NA 2.6 vs. 0.7 (p < 0.0001)
Kanji S, 2012 [55] 10ac 24ac 0
Tongyaoo S, 2013 [56] NA NA 5.9 vs. 2.0d
Atrial fibrillation vs. no atrial fibrillation.
AF atrial fibrillation, LOS length of stay, NA not available, NS not significant.
aMedian.
bData focusing on septic shock patients.
cData with new-onset AF alone.
dp value not provided.
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rence of new-onset AF. On the other hand, previous treat-
ment with calcium channel blockers was reported as a risk
factor of new-onset AF in one study, in which 70% of the
patients received calcium channel blockers for hyperten-
sion [50]. Although hypertension was a major risk factor
for AF in general populations, the authors of the study did
not take a past history of hypertension into consideration
in their analysis. As the authors discussed in their article,
the association between previous medication with calcium
channel blockers and new-onset AF was not conclusive.
Walkey et al. reported a negative association between a
previous history of hypertension and new-onset AF among
septic patients (odds ratio = 0.88) [54]. As this study was a
retrospective observational study using disease classifica-
tion codes in in-patient databases, there might have been
a reporting bias (e.g., less frequent coding of chronic co-
morbidities). To solve this uncertainty, future studies for
risk factors of AF in the critically ill should include both a










































Figure 2 Reported hospital mortality rates in patients with and without atr
non-AF patients.treatment, especially β-blockers and calcium channel
blockers.
Walkey et al. presented increased risks of stroke asso-
ciated with new-onset AF in septic shock patients [54].
In a recent prospective observational study on SVA,
CHADS2 and CHA2DS2-VASc predicted SVA-related
arterial thromboembolic events in critically ill patients,
and the most accurate threshold was a CHADS2 score
of 4 or higher [66]. On the other hand, Kanji S et al.
reported that only 16% of new-onset AF patients in their
study were given systemic anticoagulation and the inci-
dence of stroke was 0% during the course of AF [55].
They also reported that 9% of patients with systemic
anticoagulation had a bleeding event that required blood
transfusion. Although ACC/AHA/ESC practice guide-
lines recommended anticoagulation for new-onset AF of
more than 48 h of duration in the general population
[33], it is currently unclear whether non-cardiac critically
ill patients with new-onset AF should be anticoagulated




















ial fibrillation. AF: atrial fibrillation, gray bar: AF patients, white bar:
Table 6 Efficacy of treatment for new-onset atrial fibrillation
Author, year [ref] Study design Severity score Observation period Intervention Conversion rate Hospital mortality (%)
Balser JR, 1998 [58] Randomized controlled APACHE III 59 Within 2 h Esmolol 59.1% [20/34] p = 0.067 31
65 Diltiazem 27.3% [6/22] 38
Seguin P, 2006 [51] Prospective observational SAPS II 47 10 ± 10 h DC 100% [3/3] NA 31.2
Amiodarone 100% [4/4]
Digoxin 100% [1/1]
No intervention 100% [4/4]
Sleeswijk ME, 2008 [59] Prospective observational APACHE II 19 Within 24 h MgSO4-amiodarone step-up scheme 93.1% [27/29] NA 37.9
Meierhenrich R, 2010 [53] Prospective observational SAPS II 31a NA DC (17/49) 85.7% [42/49]c NA 48ad
34b Amiodarone (36/49) 23bd
Digitalis (31/49)
β-Blockers (25/49)
Kanji S, 2012 [55] Retrospective observational APACHE II 22.6 Within 24 h DCe 26.9% [7/26] NA 32
Amiodaronef 87.4% [90/103]
Sotalol 100% [2/2]
Rate control 75% [21/28]
AF atrial fibrillation, DC direct current cardioversion, LOS length of stay, MgSO4 magnesium sulfate, NA not available.
aNew-onset AF, no septic shock.
bNew-onset AF and septic shock.
cThe efficacy of each intervention was unknown because of a combination of these interventions.
dSixty-day mortality.
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benefits of anticoagulation when a critically ill patient
develops new-onset AF.
As for AF prevention, we excluded two RCTs because
of focusing on patients after lung resection, although
they were conducted in the ICU [60,61]. The first study
compared preemptive amiodarone and MgSO4 adminis-
tration with a control, and the second study compared
acebutolol and diltiazem with placebo. In the first study,
both amiodarone and MgSO4 administration decreased
new-onset AF and shortened ICU length of stay and
hospital length of stay [60]. In the second study, although
patients on acebutolol had a numerically lower incidence
of new-onset AF than those on diltiazem and placebo, the
difference did not reach statistical significance (p = 0.067)
[61]. In addition, among the seven prevention studies we
excluded from our systematic review, there were two RCTs
for prevention of new-onset AF, one after transthoracic
esophagectomy [67] and one after pulmonary resection
[64]. In both studies, patients who received amiodarone
had significantly less postoperative AF. In another study
for patients undergoing pneumonectomy, prophylactic
MgSO4 administration was also reported to reduce the in-
cidence of SVA [68]. As for AF treatment, amiodarone and
MgSO4-amiodarone step-up therapy achieved a conversion
rate of more than 90% in mixed ICU patients who devel-
oped new-onset AF [59]. Although these findings suggest
that amiodarone, MgSO4, or their combination might be
effective to prevent or treat new-onset AF in specific
groups in the ICU, more studies are needed to evaluate the
effect of these drugs in the general ICU population.
This review has several limitations. First, we included
only 12 studies and their quality of evidence was generally
low. Since AF has a worse prognosis compared with other
SVAs and AF in the general population and needs specific
attention on anticoagulation, we strictly limited to studies
that had focused on new-onset AF and excluded studies
on SVA [43,44,69]. For example, three of four studies
included in a previous systematic review on treatment for
new-onset AF in non-cardiac critically ill patients were
excluded in our review because these three studies also
included patients with SVA [36]. We could not find any
clinical trials on treatment for new-onset AF that were
published after this systematic review. Second, there was a
strong heterogeneity between included studies with re-
spect to selected population and definitions of variables
that had been measured, so that we could not derive con-
clusive statements especially on the effect of prevention
and treatment of new-onset AF from this review.
Conclusions
In this systematic review, we found that new-onset AF
occurred in 5%–15% of general non-cardiac critically ill
patients. Patients with new-onset AF had poor outcomescompared with those without AF. Despite the high inci-
dence of new-onset AF in the general ICU population,
currently available information for AF, especially for
management (prevention, treatment, and anticoagulation),
is quite limited. Further research is urgently needed to
improve our understanding of new-onset AF in critically
ill patients.
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